November 30, 2022

Biotech Strategy Blog: Sally Church's List of Emerging biotechs and novel IO concepts to watch out for

October 27, 2022

The Bio Report: Learning from “Elite” Responders to Develop Better Immunotherapies

August 31, 2022

Scientific Inquirer: Industry Matters: From Elite Responders to M2 macrophages – OncoResponse’s approach to cancer immunotherapy

August 17, 2022

BioBoss Podcast with John Simboli: #50 - Cliff Stocks: Founder and CEO, OncoResponse

May 10, 2022

BioSpace: OncoResponse IDs Elite Cancer Responders’ Antibodies to Make IO More Effective

February 15, 2022

Business Wire: Oxford Finance Announces the Closing of a $50 Million Credit Facility With OncoResponse

July, 2021

AACR Journals: Abstract 1719: OR2805, an anti-CD163 antibody derived from an elite responder to checkpoint inhibitor therapy relieves immunosuppression caused by tumor associated macrophages

July, 2021

AACR Journals: Abstract 1638: Discovery and preclinical characterization of anti-Siglec-15 antibodies that rescue T cells from macrophage-mediated immune suppression

March 31, 2021

GeekWire: Seattle biotech OncoResponse raises $40.6M to create antibody-based treatments for cancer

January 16, 2020

Contract Pharma: Just - Evotec, OncoResponse Enter Antibody Alliance

September 12, 2018

BioWorld: OncoResponse completes $40M series B, shifting from discovery to development

September 11, 2018

ENDPOINTS: Focusing on the tumor microenvironment, OncoResponse garners $40 million for the next stage of the R&D journey

September 11, 2018

BioCentury: OncoResponse moves into clinic with $40M series B

September 11, 2018

FierceBiotech: OncoResponse raises $40M for cancer patient-sourced antibodies

September 11, 2018

Xconomy: OncoResponse Nabs $40M for Cancer Drugs Based On Survivors’ Antibodies

March 29, 2017

Puget Sound Business Journal: Theraclone venture OncoResponse reports $29.5M in funding

August 8, 2016

BioCentury: Emerging Company Profile: Interrogating Immunity

October 7, 2015

BioWorld: Theraclone, MD Anderson target super-responders in IO start-up

October 6, 2015

Xconomy: Houston’s M.D. Anderson, Theraclone Launch Immunotherapy Startup

October 6, 2015

FierceBiotech: Hub-building MD Anderson partners with Theraclone on $9.5M biotech startup

October 6, 2015

GEN: MD Anderson, Theraclone Launch Immuno-Oncology Antibody Discovery Company